Klaus Koefoed

This inventor holds 15 USPTO granted patents and 8 published patent applications, plus 4 CIPO patents and 11 EPO patents. Top assignees: Symphogen A/s, Genentech, Inc., Les Laboratoires Servier. Active years: 2011-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Klaus Koefoed. Retrieved from https://idiyas.com/inventor/klaus-koefoed

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 15 (Patent Applications = 8)

% Patents Active = 53.3

CIPO Patents = 4 (Patent Applications = 5)

EPO Patents = 11 (Patent Applications = 11)

Average Co-Inventor Count = 8.3

ph-index = 5

Forward Citations = 79(Granted Patents)

Location History:

Lyngby, DK (2017 - 2020)
København S, DK (2015 - 2022)
Copenhagen, DK (2011 - 2024)

Company Filing History:

Les Laboratoires Servier

patents

Years Active: 2011-2026

Loading Chart...

15 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12577302 - ANTI-TIM-3 ANTIBODIES AND COMPOSITIONS (2026-03-17),

2. 12030942 - Anti-PD-1 antibodies and compositions (2024-07-09),

3. 11390674 - Anti-TIM-3 antibodies and compositions (2022-07-19),

4. 11359018 - Anti-PD-1 antibodies and compositions (2022-06-14),

5. 11034765 - Anti-PD-1 antibodies and compositions (2021-06-15),

6. 10570192 - Anti-wall teichoic antibodies and conjugates (2020-02-25),

7. 10450376 - Anti-MET antibodies and compositions (2019-10-22),

8. 10058610 - Methods for treating cancer by administering humanized pan-HER antibody compositions (2018-08-28),

9. 9895450 - Anti-wall teichoic antibodies and conjugates (2018-02-20),

10. 9884126 - Anti-wall teichoic antibodies and conjugates (2018-02-06),

11. 9803002 - Anti-wall teichoic antibodies and conjugates (2017-10-31),

12. 9527913 - Humanized pan-HER antibody compositions (2016-12-27),

13. 9217039 - Anti-HER3 antibodies and compositions (2015-12-22),

14. 8414896 - Recombinant anti-epidermal growth factor receptor antibody compositions (2013-04-09),

15. 7887805 - Recombinant anti-epidermal growth factor receptor antibody compositions (2011-02-15),

Title: Klaus Koefoed: A Pioneer in Antibody Innovation

Introduction

Klaus Koefoed is a notable inventor based in København S, Denmark, recognized for his significant contributions to the field of biotechnology. With a remarkable portfolio of 13 patents, he has paved the way for advancements in cancer treatment through innovative antibody therapies.

Latest Patents

Koefoed's latest inventions include two groundbreaking patents:

1. **Anti-TIM-3 antibodies and compositions**: This invention pertains to anti-TIM-3 antibodies and their compositions, designed to enhance immunity in patients, particularly for cancer treatment.

2. **Anti-PD-1 antibodies and compositions**: This patent focuses on anti-PD-1 antibodies and the methods involved in utilizing these antibodies for treating diseases related to PD-1 activity, also with an emphasis on cancer.

Career Highlights

Throughout his career, Klaus Koefoed has worked with prominent companies in the biotechnology sector, including Symphogen A/S and Genentech, Inc. His role in these organizations has been crucial in advancing research and development in monoclonal antibody therapies.

Collaborations

In his journey, Koefoed has collaborated with esteemed colleagues such as Mikkel Wandahl Pedersen and Peter Sejer Andersen. Together, they have fostered innovation and contributed to the comprehension of antibody-mediated therapies.

Conclusion

Klaus Koefoed stands out as an influential figure in the world of biopharmaceuticals, thanks to his innovative patent portfolio and collaborative spirit. His work continues to inspire advances in cancer treatment, highlighting the importance of antibody-based therapies in modern medicine.

Profile summary based on public USPTO records.